肾透明细胞癌治疗进展

打开文本图片集

中图分类号：R737.11 文献标志码：A 文章编号：1001-5779（2025）07-0630-07

DOI：10.3969/j.issn. 1001-5779.2025.07.002

Advancesinthetreatmentofclearcellrenalcellcarcinoma

DING Tao，WANG Xiao-ling （DepartmentofLaboratoryMedicine，TheFirstAfiliatedHospitalofGannanMedicalUniversity，Ganzhou，Jiangxi341000）

Abstract：Clear cellrenal cellcarcinoma（ccRCC）isthemost commonsubtypeof renalcancer，featuring clinical characteristics suchas high ratesof metastasis，recurrnce，andresistance toradiotherapyand chemotherapy.Withits increasing incidence，ccRCChasbecomeoneof the majordiseases threatening public health.Although traditionaltreatment methodslikesurgical resection，cytokine therapy，and targeteddrug therapycanimprove patients'prognosis toacertain extent，problems suchas limited efficacyand drug resistance stillexist.With theadvancement of molecular biology techniques，，biomarkers closelyassociated with ccRCC have been continuouslyuncovered.Among them，mutations n the Von Hippel-Lindau （ VHL ）gene and the consequent persistent activation of the hypoxia-inducible factor- 2α （HIF- 2α ） pathway represent key mechanisms driving the progression of ccRCC.Belzutifan，an HIF- 2α inhibitor developed based onthis mechanism，has demonstrated favorablesafety profilesandantitumorefficacyin clinical studies，ofering novel insights into precision-targeted therapy for ccRCC.Meanwhile，nanotechnology has also shown extensive application prospects in theearlydiagnosisanddrug delivery for ccRCC，as itcansignificantlyenhancedrug targeting，thereby improvingantitumor eficacywhilereducing toxicsideefects.Thisarticlesystematicall reviewsthepathogenesis， conventional therapeuticstrategies，and emerging treatmentsofccRCC，providing acritical foundation foroptimizing clinical therapeutic regimens and guiding future research priorities.

Keywords：Carcinoma，renal cell；Treatment；Drug resistance，tumors；Nanotechnology

肾癌（Renalcellcarcinoma，RCC）是泌尿系统常见肿瘤之一，在男性恶性肿瘤中位居第六，在女性恶性肿瘤中位居第十[]。（剩余15016字）